Reuters logo
BRIEF-Morphosys ag in ongoing phase 1/2a study, anti-cd38 antibody continues to show encouraging clinical response rates in heavily pre-treated multiple myeloma patients
October 17, 2016 / 5:36 AM / a year ago

BRIEF-Morphosys ag in ongoing phase 1/2a study, anti-cd38 antibody continues to show encouraging clinical response rates in heavily pre-treated multiple myeloma patients

Morphosys Ag

* In ongoing phase 1/2a study, anti-cd38 antibody continues to show encouraging clinical response rates in heavily pre-treated multiple myeloma patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below